Document is current

Article History

Received: 9 January 2024

Accepted: 4 June 2024

First Online: 16 July 2024

Declarations

:

: The trial was approved by the Institutional Review Board (South Mediterranean III Comité de Protection des Personnes on December 5, 2019, no. 19.10.24.60836). All patients or relatives provided written informed consent.

: Not applicable.

: Robin Deleris has nothing to disclose. Côme Bureau has nothing to disclose. Saïd Lebbah has nothing to disclose. Maxens Decavèle reports support for attending meetings and/or travel from Isis medical, outside the submitted work. Martin Dres reports personal fees and grants from Lungpacer unrelated to the work submitted. Julien Mayaux reports support for attending meetings and/or travel from Gilead, outside the submitted work. Thomas Similowski reports grants from Lungpacer, consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc, Novartis France, TEVA France and Vitalaire, outside the submitted work. Agnès Dechartres reports grants from the French Ministry of Health. Alexandre Demoule reports grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees and non-financial support from Fisher & Paykel, grants from the French Ministry of Health, grants from Assistance Publique – Hôpitaux de Paris, personal fees from Getinge, grants, personal fees and non-financial support from Respinor, grants, personal fees and non-financial support from Lungpacer, personal fees from Lowenstein and personal fees from Gilead, outside the submitted work.